Plain-English translation of NCT06905587 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing methylphenidate, a stimulant medication commonly used to treat ADHD, to see if it can help reduce severe fatigue in people who were treated for brain tumors as children or teens. Cancer-related fatigue is a real problem that many young brain tumor survivors struggle with long after treatment ends. If this medication helps, it could offer patients a new treatment option.
Young brain tumor survivors often experience extreme tiredness that can last for years after treatment, but doctors don't yet have proven treatments to help. This trial aims to fill that gap by testing whether this medication, which is already safe and well-known, could reduce this debilitating fatigue.
You likely qualify if…
You likely don't qualify if…
If you join, you'll take either the medication or a placebo (a dummy pill that looks identical) for 6 weeks, then have a 4-week break where you take nothing, then switch to the other treatment for another 6 weeks. Your doctor won't tell you which is which—that's the 'double-blind' part—so both you and the researchers are testing fairly. You'll complete questionnaires about your fatigue and energy levels throughout the study to help researchers see if the treatment is working.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
Denmark